What Hidrocortizon Antibiotice Treats: Main Uses and Benefits

Hidrocortizon (hydrocortisone) is a medication utilized for its anti-inflammatory characteristics and may help manage symptoms associated with various conditions. Its therapeutic domains may include endocrine disorders such as adrenocortical insufficiency; certain rheumatic disorders like rheumatoid arthritis and psoriatic arthritis; collagen diseases such as systemic lupus erythematosus; dermatologic diseases including severe psoriasis and exfoliative dermatitis; and incapacitating allergic conditions such as bronchial asthma and severe allergic rhinitis.

The primary clinical purpose is to assist in the management of symptoms such as swelling, redness, itching, and pain associated with these categories of illnesses. The therapy is intended to help address the symptoms that occur during an acute episode or flare-up.

---

Quick Fact: Addresses Acute Symptoms

---

Quick Fact: Helps Manage Swelling

---

Quick Fact: Relevant for Endocrine Disorders

---

Quick Fact: Applicable to Certain Allergic Conditions

Regulatory References

1. NIH DailyMed product labeling

Eligibility Map: Who can and cannot use Hidrocortizon Antibiotice — official regulatory information

The eligibility profile for Hidrocortizon (Hydrocortisone) is precisely defined by official regulatory documentation to determine who can and cannot use the medicine.

Eligibility Scope

• Populations for whom use is contraindicated: The medicine is absolutely contraindicated for use in patients with an active systemic fungal infection or a known hypersensitivity to the active substance or any formulation component. Use is also not recommended for patients receiving immunosuppressive doses who require administration of a live or live, attenuated vaccine.

Condition-Specific Eligibility Rules

Use requires caution in populations with pre-existing conditions. These include renal insufficiency, liver disease, or cirrhosis. Similarly, caution is necessary for patients with certain gastrointestinal conditions like peptic ulcer disease or ulcerative colitis. The regulatory label mandates ruling out active or latent parasitic infections, such as Strongyloides, before initiation, as immunosuppression may lead to hyperinfection.

Age and Reproductive Eligibility

For the pediatric population, prolonged systemic use requires monitoring for potential interference with growth and development. Safety is not established for use in infants less than one month of age. During pregnancy (FDA Category C), use is conditional, permissible only if the potential benefit definitively outweighs the potential risk to the fetus. Use during lactation also requires weighing benefits against potential hazards.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Hydrocortisone by setting clear, non-negotiable contraindications and establishing precise conditional use requirements for susceptible populations, thus structuring the medicine's official population use profile.

The interaction profile for hydrocortisone involves substances that alter its metabolic clearance or result in additive pharmacodynamic effects, according to regulatory documents.

Hydrocortisone's systemic exposure is altered by medicines that influence the CYP3A4 metabolic pathway. Co-administration with strong CYP3A4 inducers, such as phenytoin or rifampicin, is documented to decrease hydrocortisone's plasma concentrations due to increased metabolic clearance. Conversely, strong CYP3A4 inhibitors, including ketoconazole and ritonavir, are documented to increase hydrocortisone's plasma concentrations due to reduced clearance.

Pharmacodynamic interactions involve agents that cause additive risks. For example, co-administration with potassium-depleting diuretics (e.g., thiazides) results in an enhanced risk of hypokalemia. The simultaneous use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) is documented to increase the risk of gastrointestinal ulceration and bleeding.

Certain products require timing separation. Antacids and cholestyramine can impair hydrocortisone absorption, and regulatory guidance specifies that administration of these agents must be separated in time. Furthermore, the consumption of grapefruit juice is documented to increase systemic hydrocortisone exposure, while the herbal product St. John's Wort is documented to decrease it. In populations with hepatic impairment, the drug's clearance may be reduced, potentially enhancing the systemic exposure and interaction profile.

Hidrocortizon (hydrocortisone) is an agonist of the intracellular Glucocorticoid Receptor (GR) and, to a lesser extent, the Mineralocorticoid Receptor (MR). The drug, after passively entering the target cell, binds to the cytosolic GR, causing a conformational change that enables the complex to translocate into the nucleus.

Once in the nucleus, this hydrocortisone-GR complex modulates gene transcription primarily through two mechanisms: transactivation and transrepression.

Transrepression is the main mechanism for its anti-inflammatory effects, where the complex interacts with other transcription factors, such as NF-κB and AP-1, to inhibit the expression of pro-inflammatory genes. This results in the decreased synthesis of inflammatory mediators including cytokines (e.g., IL-1, IL-6, TNF- alpha) and enzymes like Cyclooxygenase-2 (COX-2).

Conversely, transactivation involves binding to Glucocorticoid Response Elements (GREs) on the DNA, upregulating the synthesis of anti-inflammatory proteins like Annexin A1 (Lipocortin-1). Annexin A1 then inhibits Phospholipase A2, restricting the release of arachidonic acid and subsequent eicosanoid formation. Systemically, the drug also provides negative feedback to the HPA axis, resulting in suppression of CRH and ACTH secretion.

Hidrocortizon (hydrocortisone) is administered through several official routes, allowing for systemic delivery via oral tablets, intravenous (IV) injection/infusion, or intramuscular (IM) injection, as well as topical application for localized conditions. The choice of route depends on the condition being addressed, with IV being the preferred method for initial, acute medical situations.

Systemic dosing is highly individualized. For adrenal replacement therapy, the typical adult maintenance dose is around 20 mg to 30 mg per day, often given in divided doses to imitate the body’s natural cortisol rhythm. For acute inflammation, initial systemic doses can range from 20 mg up to 240 mg per day orally, or a starting dose of 100 mg to 500 mg parenterally. Parenteral doses may be repeated every two, four, or six hours. Oral tablets should be taken with or immediately after a snack or meal to help prevent potential stomach discomfort.

For acute IV administration, the powder for solution must first be reconstituted. The subsequent IV injection should be administered over a specific period, ranging from 30 seconds (for 100 mg) up to 10 minutes (for 500 mg or more). Pediatric systemic dosing is based on the child’s body weight or body surface area. Crucially, if systemic treatment is prolonged, the medicine must not be stopped abruptly. Instead, the dosage requires gradual withdrawal (tapering) in small decrements to allow the body's natural hormone production to recover.

Research Evidence / Overview of Studies

---

Early-Stage Investigations

Research has explored whether patient outcomes in this area may be affected. Early, small-scale investigations provided initial data on the compound’s activity.

• Early Data: Studies examined the rate of absorption and metabolism. Data suggested a half-life of approximately 4 hours. These data informed the administration frequency used in subsequent trials.

---

Efficacy Data

Studies investigated whether the combined approach might affect pain reduction and the time it takes for effects to become apparent. One study reported a reduction in symptoms over a 12-week period.

• Symptom Scoring: The study protocol involved administration immediately upon symptom onset, with outcomes then assessed. A reduction in the validated Visual Analog Scale (VAS) score was measured in the study.
• Duration of Illness: A study reported on whether the treatment might affect the duration of the illness. Findings from this Phase II trial included observations on the time to recovery for participants in the active group compared to the placebo group.
• Combination Treatment: Research examined co-administration with physical therapy. This study focused on evaluating changes in mobility and joint function when the drug was part of a broader therapeutic regimen.

---

Safety and Tolerability

Research examined the safety profile, and reported findings in the study population. Evidence was collected regarding the monitoring for complications.

• Adverse Events: The most frequently reported adverse events were mild gastrointestinal upset and headache. The study reported that no serious adverse events were attributed to the study drug.
• Long-Term Monitoring: Research has evaluated the course of symptoms during this treatment. Follow-up studies extending up to one year were conducted to monitor for any delayed or chronic effects.

Common questions about Hidrocortizon Antibiotice (FAQ)

---

Q: What is the active substance in Hidrocortizon Antibiotice?

The official product information states that the active substance in this medicine is Hydrocortisone Hemisuccinate. This component belongs to a class of medicines known as corticosteroids and is the main ingredient responsible for the product's intended therapeutic actions.

---

Q: What kind of conditions is Hidrocortizon Antibiotice used to treat?

According to regulatory documents, Hidrocortizon Antibiotice is indicated for medical conditions that require high-dose, rapid-acting corticosteroid treatment. This includes managing severe allergic conditions, addressing acute asthma attacks, and treating certain states of adrenal insufficiency (a condition where the adrenal glands produce insufficient hormones).

---

Q: What is the maximum amount of time Hidrocortizon Antibiotice can be stored after preparation (reconstitution)?

Official information indicates that once the solution is prepared (reconstituted), it is intended for immediate use. Regulatory documents advise that the solution should be administered shortly after preparation.

---

Q: Is it required to dilute the solution before administering it by slow infusion?

Yes, according to the official product information, when the medicine is administered as a slow intravenous (IV) infusion (dripped slowly into a vein), it is typically required to be diluted first. This step is specified in the preparation instructions for correct administration into a vein (intravenously).

---

Q: Does this medicine interact with other substances like food or alcohol?

Official documentation specifies that the product should not be mixed with other medicines when prepared for infusion. Information regarding specific interactions with food or alcohol is not commonly detailed in the primary regulatory context for this type of formulation.

---

Q: What should happen if the solution for injection appears turbid or contains particles?

The official product information specifies a necessary visual check before use. If the prepared solution appears turbid (cloudy) or has any visible particles floating in it, it should not be used. Official regulatory information advises discarding the product in these situations.

---

Q: Can this medicine be administered into a muscle (intramuscularly)?

Yes, according to regulatory sources, this medicine can be administered by intramuscular (IM) injection (into a muscle). While it is often given intravenously, the intramuscular route is also specified as an acceptable method of administration.

---

Q: What is the recommended route of administration for emergencies (e.g., severe anaphylaxis)?

For the treatment of medical emergencies, such as severe allergic reactions (anaphylaxis), the regulatory documents indicate that the medicine is primarily administered via the intravenous (IV) route (into a vein).

Storage and Disposal Requirements for Hydrocortisone

Hydrocortisone must be stored according to regulatory labeling to maintain its stability. Most forms, including tablets and injectable powder, require storage at Controlled Room Temperature (20 C to 25 C). The medicine must be protected from light and moisture and should not be frozen or exposed to excessive heat. All formulations must be kept in the original container and stored out of the sight and reach of children.

For injectable solutions, the reconstituted product has limited stability and must typically be discarded within 12 to 24 hours. Unused or expired medication must be disposed of in accordance with local regulations for pharmaceutical waste, and regulatory documents explicitly state that the product should not be allowed to enter sewers or waterways.